---
title: "Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284784032.md"
description: "Genprex announced that the Israel Patent Office granted a patent for its Reqorsa Gene Therapy in combination with PD-1 antibodies for cancer treatment. This patent strengthens Genprex's global intellectual property position, complementing existing patents in the U.S., Japan, China, and Europe. The company aims to address the rising lung cancer burden in Israel, highlighting the strategic importance of this patent for its future operations. Genprex focuses on developing gene therapies for cancer and diabetes, with Reqorsa targeting lung cancer markets worldwide."
datetime: "2026-04-30T13:35:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284784032.md)
  - [en](https://longbridge.com/en/news/284784032.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284784032.md)
---

# Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Genprex ( (GNPX) ) has provided an announcement.

On April 30, 2026, Genprex announced that the Israel Patent Office granted a patent covering the use of its Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. This new protection adds to previously granted Reqorsa combination patents in major markets including the U.S., Japan, China and Europe, strengthening the company’s global IP position in oncology.

The company framed the Israeli patent as a strategic expansion that supports its development of Reqorsa with established cancer drugs for lung cancer patients. The announcement highlighted Israel’s rising lung cancer burden and high mortality rates, underscoring the commercial and clinical relevance of securing patent coverage in that market for Genprex’s future operations and stakeholder interests.

**More about Genprex**

Genprex, Inc. is a biotechnology company developing gene therapies for cancer and diabetes, with a key focus on its lead candidate Reqorsa Gene Therapy (quaratusugene ozeplasmid). Reqorsa is initially being developed in combination with approved cancer drugs and immunotherapies to treat lung cancer, targeting markets worldwide where the company has been building an extensive intellectual property portfolio.

**Average Trading Volume:** 908,343

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $8.01M

For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.

### Related Stocks

- [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md)

## Related News & Research

- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy](https://longbridge.com/en/news/286655317.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements](https://longbridge.com/en/news/286580579.md)